SGLT2 inhibitors and cardiovascular risk: Lessons learned from the EMPA-REG Outcome study

Muhammad Abdulghani, Stefano Del Prato, Robert Chilton, Ralph A. De Fronzo

Research output: Contribution to journalArticlepeer-review

179 Citations (Scopus)

Abstract

Although cardiovascular (CV) mortality is the principal cause of death in individuals with type 2 diabetes (T2DM), reduction of plasma glucose concentration has little effect on CV disease (CVD) risk. Thus, novel strategies to reduce CVD risk in T2DM patients are needed. The recently published BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) study demonstrated that in T2DM patients with high CVD risk empagliflozin reduced the primary major adverse cardiac event end point (CV death, nonfatal myocardial infarction, nonfatal stroke) by 14%. This beneficial effect was driven by a 38% reduction in CV mortality with no significant decrease in nonfatal myocardial infarction or stroke. Empagliflozin also caused a 35% reduction in hospitalization for heart failure without affecting hospitalization for unstable angina. Although sodium-glucose cotransporter 2 inhibitors exert multiple metabolic benefits (decreases in HbA1c, body weight, and blood pressure and an increase in HDL cholesterol), all of which could reduce CVD risk, it is unlikely that the reduction in CV mortality can be explained by empagliflozin's metabolic effects. More likely, hemodynamic effects, specifically reduced blood pressure and decreased extracellular volume, are responsible for the reduction in CV mortality and heart failure hospitalization. In this Perspective, we will discuss possible mechanisms for these beneficial effects of empagliflozin and their implications for the care of T2DM patients.

Original languageEnglish
Pages (from-to)717-725
Number of pages9
JournalDiabetes care
Volume39
Issue number5
DOIs
Publication statusPublished - 1 May 2016

Fingerprint Dive into the research topics of 'SGLT2 inhibitors and cardiovascular risk: Lessons learned from the EMPA-REG Outcome study'. Together they form a unique fingerprint.

Cite this